Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
Exercise / conversionCommon shares without par value | 71,000 | $38.40 | $2,726,400.00 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 21:59 UTC |
Wainer Andrea FExecutive Vice President
|
SaleCommon shares without par value | 1,188 | $85.13 | $101,134.44 |
DisclosureSEC source: 0001179110-19-008064 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,260 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC |
ALLEN HUBERT LExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · derivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 165,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC |
ALLEN HUBERT LExecutive Vice President
|
SaleCommon shares without par value | 165,000 | $85.00 | $14,025,000.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,010 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:19 UTC |
ALLEN HUBERT LExecutive Vice President
|
Exercise / conversionCommon shares without par value | 165,000 | $34.94 | $5,765,100.00 |
DisclosureSEC source: 0001179110-19-008034 · edgar.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 46,900 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · derivative · entry 3 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 46,900 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC |
CAPEK JOHN MExecutive Vice President
|
SaleCommon shares without par value | 46,900 | $85.00 | $3,986,500.00 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · nonDerivative · entry 2 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,535 Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 21:20 UTC |
CAPEK JOHN MExecutive Vice President
|
Exercise / conversionCommon shares without par value | 46,900 | $26.19 | $1,228,212.51 |
DisclosureSEC source: 0001179110-19-008035 · edgar.xml · nonDerivative · entry 1 CAPEK JOHN M · CIK 0001328034 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2019 Filed Jun 13, 2019 21:12 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
SaleCommon shares without par value | 3,331 | $82.00 | $273,142.00 |
DisclosureSEC source: 0001179110-19-007613 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,148 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 73,424 | $0.00 Strike: $48.90 | $0.00 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · derivative · entry 4 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,268 Underlying: Common shares · 73,424 shares Expires 2025-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC |
LANE ANDREW HExecutive Vice President
|
SaleCommon shares without par value | 73,424 | $81.42 | $5,978,196.76 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · nonDerivative · entry 2 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,938 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.41 to $81.505, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 21:03 UTC |
LANE ANDREW HExecutive Vice President
|
Exercise / conversionCommon shares without par value | 73,424 | $48.90 | $3,590,433.60 |
DisclosureSEC source: 0001179110-19-007717 · edgar.xml · nonDerivative · entry 1 LANE ANDREW H · CIK 0001643735 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:12 UTC |
Salvadori Daniel Gesua SiveExecutive Vice President
|
SaleCommon shares without par value | 7,269 | $82.00 | $596,058.00 |
DisclosureSEC source: 0001179110-19-007613 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,479 Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC |
Earnhardt Lisa DExecutive Vice President
|
GrantOption (right to buy) · Derivative | 91,367 | $0.00 Strike: $80.98 | $0.00 |
DisclosureSEC source: 0001179110-19-007549 · edgar.xml · derivative · entry 3 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,367 Underlying: Common shares · 91,367 shares Expires 2029-06-09 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,455 on June 10, 2020, 30,456 on June 10, 2021, and 30,456 on June 10, 2022. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC |
Earnhardt Lisa DExecutive Vice President
|
GrantCommon shares without par value | 39,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007549 · edgar.xml · nonDerivative · entry 2 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,946 F2 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with the award vesting on June 10, 2022. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:08 UTC |
Earnhardt Lisa DExecutive Vice President
|
GrantCommon shares without par value | 17,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007549 · edgar.xml · nonDerivative · entry 1 Earnhardt Lisa D · CIK 0001530893 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,431 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:07 UTC |
Ford Robert BPresident and COO
|
GiftCommon shares without par value | 18,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007400 · edgar.xml · nonDerivative · entry 2 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Indirect · Ford Family Trust Disclosed balance after: 114,325 F1 · balance_after: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:07 UTC |
Ford Robert BPresident and COO
|
GiftCommon shares without par value | 18,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007400 · edgar.xml · nonDerivative · entry 1 Ford Robert B · CIK 0001612571 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,057 Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:37 UTC |
Ginascol John FExecutive Vice President
|
GrantOption (right to buy) · Derivative | 62,725 | $0.00 Strike: $76.12 | $0.00 |
DisclosureSEC source: 0001179110-19-007233 · edgar.xml · derivative · entry 2 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,725 Underlying: Common shares · 62,725 shares Expires 2029-06-02 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,908 on June 3, 2020, 20,908 on June 3, 2021, and 20,909 on June 3, 2022. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:37 UTC |
Ginascol John FExecutive Vice President
|
GrantCommon shares without par value | 11,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007233 · edgar.xml · nonDerivative · entry 1 Ginascol John F · CIK 0001778075 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,584 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:39 UTC |
Wainer Andrea FExecutive Vice President
|
GrantOption (right to buy) · Derivative | 62,725 | $0.00 Strike: $76.12 | $0.00 |
DisclosureSEC source: 0001179110-19-007238 · edgar.xml · derivative · entry 2 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,725 Underlying: Common shares · 62,725 shares Expires 2029-06-02 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,908 on June 3, 2020, 20,908 on June 3, 2021, and 20,909 on June 3, 2022. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 22:39 UTC |
Wainer Andrea FExecutive Vice President
|
GrantCommon shares without par value | 11,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-007238 · edgar.xml · nonDerivative · entry 1 Wainer Andrea F · CIK 0001778070 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,448 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 56,735 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 9 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common shares · 56,735 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 53,163 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 8 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common shares · 53,163 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 175,164 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 7 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 175,164 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 165,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · derivative · entry 6 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 165,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
SaleCommon shares without par value | 450,062 | $75.52 | $33,988,727.25 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 5 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,745 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.50 to $75.70, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionCommon shares without par value | 56,735 | $38.40 | $2,178,624.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 4 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,807 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionCommon shares without par value | 53,163 | $47.00 | $2,498,661.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 3 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionCommon shares without par value | 175,164 | $39.12 | $6,852,415.68 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 2 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:02 UTC |
Blaser Brian J.Executive Vice President
|
Exercise / conversionCommon shares without par value | 165,000 | $34.94 | $5,765,100.00 |
DisclosureSEC source: 0001179110-19-006685 · edgar.xml · nonDerivative · entry 1 Blaser Brian J · CIK 0001492289 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 50,994 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 10 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,987 Underlying: Common shares · 50,994 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 34,086 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 9 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,043 Underlying: Common shares · 34,086 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 109,657 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 8 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 109,657 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 114,692 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · derivative · entry 7 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 114,692 shares Expires 2025-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
SaleCommon shares without par value | 309,429 | $78.51 | $24,294,199.08 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 5 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,535 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.50 to $78.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionCommon shares without par value | 50,994 | $59.94 | $3,056,580.36 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionCommon shares without par value | 34,086 | $44.40 | $1,513,418.40 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionCommon shares without par value | 109,657 | $38.40 | $4,210,828.80 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2019 Filed May 6, 2019 21:04 UTC |
Watkin JaredSenior Vice President
|
Exercise / conversionCommon shares without par value | 114,692 | $48.04 | $5,509,803.68 |
DisclosureSEC source: 0001179110-19-005605 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionOption (right to buy) · Derivative | 80,860 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · derivative · entry 13 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 80,860 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Tax withholdingCommon shares without par value | 57,962 | $78.11 | $4,527,411.82 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 6 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,604 Read SEC document |
| April 26, 2019 Filed Apr 29, 2019 21:35 UTC |
Contreras JaimeSenior Vice President
|
Exercise / conversionCommon shares without par value | 80,860 | $38.40 | $3,105,024.00 |
DisclosureSEC source: 0001179110-19-005257 · edgar.xml · nonDerivative · entry 5 Contreras Jaime · CIK 0001587070 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:09 UTC |
NOVAKOVIC PHEBE NDirector
|
GrantOption (right to buy) · Derivative | 10,837 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005301 · edgar.xml · derivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,837 Underlying: Common shares · 10,837 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:09 UTC |
NOVAKOVIC PHEBE NDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005301 · edgar.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,333 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:11 UTC |
McKinstry NancyDirector
|
GrantOption (right to buy) · Derivative | 10,146 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005302 · edgar.xml · derivative · entry 2 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,146 Underlying: Common shares · 10,146 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:11 UTC |
McKinstry NancyDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005302 · edgar.xml · nonDerivative · entry 1 McKinstry Nancy · CIK 0001294731 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,666 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:14 UTC |
TILTON GLENN FDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005303 · edgar.xml · nonDerivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,053 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:15 UTC |
Kumbier MichelleDirector
|
GrantCommon shares without par value | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-005304 · edgar.xml · nonDerivative · entry 1 Kumbier Michelle · CIK 0001640036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,258 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 · balance_after: Balance includes shares acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 26, 2019 Filed Apr 30, 2019 21:16 UTC |
LIDDY EDWARD MDirector
|
GrantOption (right to buy) · Derivative | 11,606 | $0.00 Strike: $78.06 | $0.00 |
DisclosureSEC source: 0001179110-19-005305 · edgar.xml · derivative · entry 2 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,606 Underlying: Common shares · 11,606 shares Expires 2029-04-25 F2 · security: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.